The FDA has issued a drug safety communication about fluconazole: long-term use at high dosages (400 to 800 mg/d) may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy.1 This risk does not appear to be associated with a single, low dose (150 mg) of fluconazole to treat vaginal yeast infection (candidiasis).
The FDA has issued a drug safety communication about fluconazole: long-term use at high dosages (400 to 800 mg/d) may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy.1 This risk does not appear to be associated with a single, low dose (150 mg) of fluconazole to treat vaginal yeast infection (candidiasis).
For indications of fluconazole other than vaginal candidiasis, the pregnancy category for fluconazole has been changed from category C to category D, meaning that there is evidence of human fetal risk based on human data but the potential benefits from the use of the drug in pregnant women with serious or life-threatening conditions may be acceptable despite its risks. The pregnancy category for a single dose of 150 mg of fluconazole for vaginal candidiasis remains category C.
Features prominent in infants with long-term exposure to high doses of fluconazole may include brachycephaly, abnormal facies, abnormal calvarial development, cleft palate, femoral bowing, thin ribs and long bones, arthrogryposis, and congenital heart disease.
More Information
Drug Information: Fluconazole
Reference
1. US Food and Drug Administration. FDA drug safety communication:
Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants
. August 3, 2011. Accessed August 11, 2011.
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Unveiling the complexities of preterm birth risk from nativity, ethnicity, and race
March 22nd 2024A recent study dissected the relationships between maternal nativity, ethnicity, and race in influencing preterm birth rates, shedding light on disparities and suggesting avenues for future research.
Read More
Study reveals link between opioid dosage and spontaneous preterm birth risk
February 21st 2024Recent research highlighted an association between the total dose of prescribed opioids during pregnancy and the heightened risk of spontaneous preterm birth, emphasizing the need for judicious opioid use in pain management for expectant mothers.
Read More